Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Eli Lilly and Company has reported positive data from the Phase III study of Cialis/finasteride in men with lower urinary tract symptoms of benign prostatic hyperplasia (LUTS/BPH) and enlarged prostates.
Subscribe to our email newsletter
According to the study, significant improvement in scores on the International Prostate Symptom Score (IPSS) were observed upon the co-administeration of Cialis 5mg once daily with finasteride, compared to placebo/finasteride.
Cialis/finasteride met the primary endpoint, by significantly improving IPSS total scores through 12 weeks versus placebo/finasteride in addition to improved IPSS total scores versus placebo/finasteride at 4 weeks and 26 weeks.
The University of Texas Southwestern Medical Center Department of Urology chairman Claus Roehrborn said, "Symptomatic improvement with 5-ARI therapy (finasteride) is observed after six to twelve months of treatment; therefore, the study aimed to understand if men with prostatic enlargement experience earlier improvement of BPH symptoms when tadalafil is co-administered with a 5-ARI therapy."
As a pre-specified secondary measure, Cialis/finasteride also improved erectile function scores compared to placebo/finasteride in men with both LUTS/BPH and erectile dysfunction at baseline.